Pubblicazioni

 

  1. The application of artificial intelligence in hepatology: a systematic review. Balsano Clara, Anna Alisi, Maurizia R. Brunetto, Pietro Invernizzi, Patrizia Burra, Fabio Piscaglia. Special Interest Group (SIG) Artificial Intelligence and Liver Diseases; Italian Association for the Study of the Liver (AISF), Digestive and Liver Disease, (2022). Jul 12: S1590-8658(21)00317-0. doi: 10.1016/j.dld.2021.06.011. Epub ahead of print. PMID: 34266794.
  2. Copper-catalyzed dicarbonyl stress in NAFLD mice: protective effects of Oleuropein treatment on liver damage. Silvano Junior Santini, Giovanni Tarantino, Antonella Iezzi, Anna Alisi, Clara Balsano, Nutrition & Metabolism (2022) 19(1), 9
  3. PaO2/FiO2 ratio forecasts COVID-19 patients' outcome regardless of age: a cross-sectional, monocentric study. Sinatti Gaia, Santini Silvano Junior, Tarantino Giovanni, Picchi Giovanna, Cosimini Benedetta, Ranfone Francesca, Casano Nicolo’, Zingaropoli Maria Antonella, Iapadre Nerio, Bianconi Simone, Armiento Antonietta, Carducci Paolo, Ciardi Maria Rosa, Mastroianni Claudio Maria, Grimaldi Alessandro, Balsano Clara. Intern Emerg Med. 2021 Oct 12:1–9. doi: 10.1007/s11739-021-02840-7. Epub ahead of print. PMID: 34637082; PMCID: PMC8505469.
  4. It is high time physicians thought of natural products for alleviating nafld. Is there sufficient evidence to use them? Giovanni Tarantino, Clara Balsano, Silvano Junior Santini, Giovanni Brienza, Irma Clemente, Benedetta Cosimini, Gaia Sinatti. Int J Mol Sci. 2021 Dec 14;22(24)
  5. Laboratory parameters related to severe disease and death in SARS-CoV-2 pneumonia: Retrospective analysis. Picchi Giovanna, Di Norcia Monica, Cofini Vincenza, Sinatti Gaia, Cosimini Benedetta, Vertolli Paola, Tonello Franco, Carucci Anna Cecilia, Necozione Stefano, Balsano Clara, Grimaldi Alessandro. J Med Virol. 2021 Oct;93(10):5886-5895. doi: 10.1002/jmv.27141. Epub 2021 Jul 8. PMID: 34138485; PMCID: PMC8427061.
  6. Age and Interleukin-15 Levels Are Independently Associated With Intima-Media Thickness in Obesity-Related NAFLD Patients. Tarantino G,Citro V, Balsano C, Capone D. Front Med (Lausanne). 2021 May 21;8:634962. doi: 10.3389/fmed.2021.634962. PMID: 34095164; PMCID: PMC8175965.
  7. Using social robot NAO for emotional support to children at a paediatric emergency department: randomized clinical trial. Silvia Rossi, PhD; Silvano Junior Santini, PhD; Daniela Di Genova, MD; Gianpaolo Maggio, Alberto Verrotti di Pianella, MD; Giovanni Farello, MD; Roberta Romualdi, MD; Anna Alisi, PhD; Alberto Eugenio Tozzi; MD; Clara Balsano, JMIR, 2021
  8. Copper concentrations are prevalently associated with antithrombin III, but also with prothrombin time and fibrinogen in patients with liver cirrhosis: a cross-sectional retrospective study. Giovanni Tarantino, Vincenzo Citro, Domenico Capone, Giuseppe, Gaudiano, Gaia Sinatti, Silvano Junior Santini, Clara Balsano. Journal of Trace Elements in Medicine and Biology (2021) – DOI: https://doi.org/10.1016/j.jtemb.2021.126802
  9. Liver-spleen axis in nonalcoholic fatty liver disease. Tarantino G, Citro V, Balsano C. Expert Rev Gastroenterol Hepatol. 2021 Apr 20:1-11. doi: 10.1080/17474124.2021.1914587
  10. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. Mario Masarone, Jacopo Troisi, Andrea Aglitti, Pietro Torre, Angelo Colucci, Marcello Dallio, Alessandro Federico, Clara Balsano & Marcello Persico Metabolomics 17, 12 (2021). https://doi.org/10.1007/s11306-020-01756-1
  11. Three Cases of COVID-19 Pneumonia in Female Patients in Italy Who Had Pulmonary Fibrosis on Follow-Up Lung Computed Tomography Imaging. Giovanna Picchi, Alessia Mari, Alessandra Ricciardi, Anna Cecilia Carucci, Gaia Sinatti, Benedetta Cosimini, Monica Di Norcia, Nerio Iapadre, Clara Balsano, Alessandro Grimaldi American Journal of Case Reports Free PMC article 2020 Nov 21;21:e926921. doi: 10.12659/AJCR.926921
  12. The pharmacological treatment of nonalcoholic fatty liver disease in children. Crudele A, Panera N, Braghini MR, Balsano C, Alisi A. Expert Rev Clin Pharmacol. 2020 Oct 19:1-9. doi: 10.1080/17512433.2020.1829468. Online ahead of print. PMID: 32981386
  13. Circulating Neutrophils of Nonalcoholic Steatohepatitis Patients Show an Activated Phenotype and Suppress T Lymphocytes Activity. Antonucci L, Porcu C, Timperi E, Santini SJ, Iannucci G, Balsano C. J Immunol Res. 2020 Jun 30;2020:4570219. doi: 10.1155/2020/4570219.
  14. Could SCGF-Beta Levels Be Associated With Inflammation Markers and Insulin Resistance in Male Patients Suffering From Obesity-Related NAFLD? Giovanni Tarantino, Vincenzo Citro, Clara Balsano, Domenico Capone. Diagnostics (Basel) 2020 Jun 11;10(6): E395. doi: 10.3390/diagnostics10060395
  15. Bridging the “last mile” gap between AI implementation andoperation: “data awareness” that matters. Cabitza F, Campagner A, Balsano C. Annals of Translational Medicine, In press, doi: 10.21037/atm.2020.03.63
  16. Oleuropein overrides Liver damage in steatotic mice. Santini SJ, Porcu C, TarantinoG, Amicarelli F, Balsano C.
  17. Gastrointestinal peptides and nonalcoholic fatty liver disease. Tarantino G, Balsano C. Curr Opin Endocrinol Diabetes Obes.2020 Feb;27(1):11-15. doi:10.1097/MED.0000000000000514.
  18. Is There a Link between Basal Metabolic Rate, Spleen Volume and Hepatic Growth Factor Levels in Patients with Obesity-Related NAFLD? Tarantino G, Citro V, Conforti P, Balsano C, Capone D. J Clin Med. 2019 Sep 20;8(10). pii: E1510. doi: 10.3390/jcm8101510.
  19. Do Transferrin Levels Predict Haemodialysis Adequacy in Patients with End-Stage Renal Disease? Tarantino G, Vinciguerra M, Ragosta A, Citro V, Conforti P, Salvati G, Sorrentino A, Barretta L, Balsano C, Capone D. Nutrients. 2019 May 20;11(5). pii: E1123. doi: 10.3390/nu11051123.
  20. Oleuropein Induces AMPK-Dependent Autophagy in NAFLD Mice, Regardless of the Gender. Porcu C, Sideri S, Martini M, Cocomazzi A, Galli A, Tarantino G, Balsano C. Int J Mol Sci. 2018 Dec 8;19(12). pii: E3948. doi: 10.3390/ijms19123948.
  21. Is copper a new target to counteract the progression of chronic diseases? Balsano C, Porcu C, Sideri S. Metallomics, 2018 Oct 19; doi: 10.1039/c8mt00219c.
  22. Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. Raparelli V, Pastori D, Pignataro SF, Vestri AR, Pignatelli P, Cangemi R, Proietti M, Davì G, Hiatt WR, Lip GYH, Corazza GR, Perticone F, Violi F, Basili S; ARAPACIS Study Collaborators. Intern Emerg Med., 2018 Aug; 13(5):651-660 doi: 10.1007/s11739-018-1922-y.
  23. Copper/MYC/CTR1 interplay: a dangerous relationship in hepatocellular carcinoma Porcu C,Antonucci L,Barbaro B,Illi B,Nasi S, Martini M, Licata A, Miele L, Grieco A, Balsano C. Oncotarget. 2018; 9:9325-9343.
  24. Oleuropein and copper: New perspectives against liver disease Balsano C, Porcu C, Sideri S, Tavolaro S. Digestive and Liver Disease, 2018 Feb; doi:https://doi.org/10.1016/j.dld.2018.01.068
  25. Prediction of carotid intima-media thickness in obese patients with low prevalence of comorbidities by serum copper bioavailability Tarantino G, Porcu C, Arciello M, Andreozzi P, Balsano C. J Gastroenterol Hepatol, 2018 6 Feb; doi: 10.1111/jgh.14104.
  26. High fat diet related liver damage anticipates the appearance of cardiac injury: the role of Klf15 and tafazzin Porcu C, Barbaro B, Antonucci L, Viscomi C, Balsano C Journal of Hepatology, 2017 Dec; doi: 10.1016/S0168-8278(17)30614-1
  27. Evaluation of tolerance to ambulatory blood pressure monitoring: Analysis of dipping profile in a large cohort of hypertensive patients. Iannucci G, Petramala L, La Torre G, Barbaro B, Balsano C, Curatulo PG, Amadei F, Paroli M, Concistrè A, Letizia C. Medicine, 2017 Dec; 96(50) pii: E9162 doi: 10.1097/MD.0000000000009162.
  28. Non-Alcoholic Fatty Liver Disease and Nutritional Implications: Special Focus on Copper.  Antonucci L, Porcu C, Iannucci G, Balsano C, Barbaro B.  Nutrients, 2017 Oct 18; 9(10) pii: E1137 doi: 10.3390/nu9101137.
  29. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. Gnani D, Romito I, Artuso S, Chierici M, De Stefanis C, Panera N, Crudele A, Ceccarelli S, Carcarino E, D'Oria V, Porru M, Giorda E, Ferrari K, Miele L, Villa E, Balsano C, Pasini D, Furlanello C, Locatelli F, Nobili V, Rota R, Leonetti C, Alisi A.  Cell Death Differ., 2017 May; 24(5):889-902. doi: 10.1038/cdd.2017.34.
  30. Small heterodimer partner 1 directly interacts with NS5A viral protein and has a key role in HCV related liver cell transformation. Conti B, Porcu C, Viscomi C, Minutolo A, Costantini S, Corazzari M, Iannucci G, Barbaro B, Balsano C. Oncotarget., 2016 Dec 20; 7(51):84575-84586. doi: 10.18632/oncotarget.12144.
  31. AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF).  Women in Hepatology Group.; Italian Association for the Study of the Liver (AISF).  Dig Liver Dis., 2016 Aug; 48(8):860-8. doi: 10.1016/j.dld.2016.04.009
  32. Core domain mutant Y220C of p53 protein has a key role in copper homeostasis in case of free fatty acids overload.  Arciello M, Longo A, Viscomi C, Capo C, Angeloni A, Rossi L, Balsano C. Biometals, 2015 Dec; 28(6):1017–29 /s10534-015-9886-0
  33. Protective Effect of the Y220C Mutant p53 Against Steatosis: Good News?Gori M, Barbaro B, Arciello M, Maggio R, Viscomi C, Longo A, Balsano C.  J Cell Physiol., 2015 Jun; 230(6):1400. doi: 10.1002/jcp.24874.
  34. Normocaloric low cholesterol diet modulates Th17/Treg balance in patients with chronic hepatitis C virus infection.Maggio R, Viscomi C, Andreozzi P, D'Ettorre G, Viscogliosi G, Barbaro B, Gori M, Vullo V, Balsano C. PLoS One, 2014 Dec 22; 9(12):e112346. doi: 10.1371/journal.pone.0112346.
  35. Effects of the olive-derived polyphenol oleuropein on human health.  Barbaro B, Toietta G, Maggio R, Arciello M, Tarocchi M, Galli A, Balsano C.  Int J Mol Sci., 2014 Oct 14; 15(10):18508-24. doi: 10.3390/ijms151018508.
  36. Could monitoring normotensives delay progression to hypertension?Iannucci G, Scarpellini E, Balsano C, Paroli M, Leone G, Giannoni MF.  Eur Rev Med Pharmacol Sci., 2014 Jun; 18(11):1680-1.
  37. Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease.Alisi A, Nobili V, Ceccarelli S, Panera N, De Stefanis C, De Vito R, Vitali R, Bedogni G, Balsano C, Cucchiara S, Stronati L.  Expert Rev Mol Diagn., 2014 Jul; 14(6):763-71. doi: 10.1586/14737159.2014.928205.
  38. Lymphocytes as liver damage mirror of hcv related adipogenesis deregulation.Minutolo A, Conti B, Viscomi C, Grelli S, Labbadia G, Balsano C. PLoS One, 2014 Mar 21; 9(3):e92343. doi: 10.1371/journal.pone.0092343.
  39. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma.Gori M, Arciello M, Balsano C.  Biomed Res Int., 2014; 2014:741465. doi: 10.1155/2014/741465.
  40. Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy.Violi F, Daví G, Hiatt W, Lip GY, Corazza GR, Perticone F, Proietti M, Pignatelli P, Vestri AR, Basili S; ARAPACIS Study Investigators. J Am Coll Cardiol, 2013 Dec 10; 62(23):2255-6. doi: 10.1016/j.jacc.2013.07.035.
  41. Exocycilic DNA adducts in a Murine Model of Non-Alcoholic Steatohepatitis.Peluso MME, Munnia A, Tarocchi M, Arciello M, Balsano C, Giese RW, Galli A.  J Carcinog Mutagen., 2013 Oct 18; S3:003. doi: 10.4172/2157-2518.S3-003
  42. Breath tests for the assessment of the orocecal transit time.Scarpellini E, Abenavoli L, Balsano C, Gabrielli M, Luzza F, Tack J.  Eur Rev Med Pharmacol Sci., 2013 Dec; 17 Suppl 2:39-44.
  43. Mitochondrial dysfunctions and altered metals homeostasis: new weapons to counteract HCV-related oxidative stress.Arciello M, Gori M, Balsano C.  Oxid Med Cell Longev., 2013;2013:971024.  doi: 10.1155/2013/971024
  44. Office normotensives with a minimal augmentation of intima-med thickness of common carotid arteries: really normotensives?Iannucci G, Balsano C, Paroli M, Scarpellini E, Leone G, Giannoni MF.  Eur Rev Med Pharmacol Sci., 2013 Dec; 17(23):3164-8.
  45. Environmental Pollution: A Tangible Risk for NAFLD Pathogenesis. Arciello M, Gori M, Maggio R, Barbaro B, Tarocchi M, Galli A, Balsano C.  Int J Mol Sci., 2013 Nov 7; 14(11):22052-66. doi: 10.3390/ijms141122052.
  46. Probiotics in non-alcoholic fatty liver disease: which and when.Abenavoli L, Scarpellini E, Rouabhia S, Balsano C, Luzza F.  Ann Hepatol., 2013 May-Jun; 12(3):357-63.
  47. Are Hedgehog and Wnt/β-catenin pathways involved in hepatitis C virus-mediated EMT? Conti B, Minutolo A, Arciello M, Balsano C. J Hepatol., 2013 Mar; 58(3):636-7. doi: 10.1016/j.jhep.2012.10.033.
  48. Focal adhesion kinase (FAK) mediates the induction of pro-oncogenic and fibrogenic phenotypes in hepatitis C virus (HCV)-infected cells.Alisi A, Arciello M, Petrini S, Conti B, Missale G, Balsano C.  PLoS One, 2012; 7(8):e44147. doi: 10.1371/journal.pone.0044147. 
  49. Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver.Gramenzi A, Conti F, Cammà C, Grieco A, Picciotto A, Furlan C, Romagno D, Costa P, Rendina M, Ancarani F, Chiaramonte M, Verucchi G, Craxì A, Bernardi M, Andreone P; AISF HepaElder Study Group.  Dig Liver Dis., 2012 Aug; 44(8):674-80. doi: 10.1016/j.dld.2012.03.009.
  50. Paradoxical prosteatotic effect of hedgehog signaling inhibition under condition of steatosis.  Gori M, Barbaro B, Arciello M, Balsano C.  Hepatology, 2012 Oct; 56(4):1587-8. doi: 10.1002/hep.25729.
  51. Cardiovascular and cerebrovascular events pre and post earthquake of April 6th 2009:the Abruzzo’s experience.  Sofia S, Melone A, Manzoli L, De Ciantis P, Varrato E, Di Filippo R, Vittorini P, Balsano C.  Am J Hypertens, 2012 May; 25(5):556-60. doi: 10.1038/ajh.2012.4.
  52. Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus- infected patients.Arciello M, Petta S, Leoni V, Iannucci G, Labbadia G, Sofia S, Camma C, Craxi A, Balsano C. Dig Liver Dis., 2012 Mar; 44(3):245-50. doi: 10.1016/j.dld.2011.10.022
  53. Hepatitis C virus (HCV) therapeutics: editing enzymes promising therapeutics targets?Alisi A, Tomaselli S, Balsano C, Gallo A.  Hepatology, 2011 Aug; 54(2):742. doi: 10.1002/hep.24409.
  54. Effect of treatment with polyunsatured fatty acid on HCV- or diet induced fatty liver. Comparcola D, Nobili V, Alisi A, Balsano C.  J Hepatol., 2011 Jun; 54(6):1325-6. doi: 10.1016/j.jhep.2011.01.019.
  55. The Activation of endotoxin/toll-like receptor4 pathway: the way to go from non-alcoholic steatohepatitis up to hepatocellular carcinoma. Alisi A, Panera N, Balsano C, Nobili V. Hepatology, 2011 Mar; 53(3):1069. doi: 10.1002/hep.24003
  56. Hepatitis C virus and alcohol: same mitotic targets but different signalling pathways.  Alisi A, Ghidinelli M, Zerbini A, Missale G, Balsano C. J Hepatol., 2011 May; 54(5):956-63. doi: 10.1016/j.jhep.2010.08.016.
  57. Regarding epithelial mesenchimal transition induced by Hepatitis C virus core protein in cholangiocarcinoma.  Balsano C, Conti B, Arciello M.  Ann Surg Oncol., 2011 Mar; 18(3):896. doi: 10.1245/s10434-010-1212-z
  58. Functions and therapeutic value of Focal Adhesion Kinase signaling during hepatocellular carcinoma development and progression.  Alisi A, Balsano C. Hepatology, 2010 Mar; 51(3):1092-3. doi: 10.1002/hep.23415
  59. 7-ketocholesterol and 5,6-secosterol modulate differently the stress-activated mitogen-activated protein kinases (MAPKs) in liver cells.  Anticoli S, Arciello M, Mancinetti A, De Martinis M, Ginaldi L, Iuliano L, Balsano C.  J Cell Physiol., 2010 Mar; 222(3):586-95. doi: 10.1002/jcp.21972.
  60. Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. Gramenzi A, Cursaro C, Margotti M, Balsano C, Spaziani A, Anticoli S, Loggi E, Salerno M, Galli S, Furlini G, Bernardi M, Andreone P.  World J Gastroenterol., 2009 Dec 21;1 5(47):5946-52
  61. Antioxidant Effects of Natural Bioactive Compounds.Balsano C, Alisi A. Curr Pharm Des. 2009;15(26):3063-73.
  62. La cultura e’ il futuro di ogni Nazione. Balsano C. Analysis, 2009 Jun.
  63. Liver fibrosis and therapeutic strategies: the goal for improving metabolism.  Balsano C, Alisi A, Nobili V.  Curr Drug Targ., 2009 Jun; 10(6):505-12. doi: 10.2174/138945009788488459.
  64. Viral Hepatitis B: Established and Emerging Therapies.  Balsano C, Alisi A.  Curr Med Chem., 2008; 15(9):930-9.
  65. Recent advances in antiviral agents: established and innovative therapies for viral hepatitis. Balsano C.  Mini Rev Med Chem., 2008 Apr; 8(4):307-18.
  66. Involvement of PI3K in HCV-related lymphoproliferative disorders.Alisi A, Giannini C, Spaziani A, Caini P, Zignego AL, Balsano C.  J Cell Physiol., 2008 Feb; 214(2):396-404. doi:10.1002/jcp.21211
  67. PKR is a novel functional direct player that coordinates skeletal muscle differentiation via p38MAPK/AKT pathways.Alisi A, Spaziani A, Anticoli S, Ghidinelli M, Balsano C. Cell signal., 2008 Mar; 20(3):534-42. doi: 10.1016/j.cellsig.2007.11.006.
  68. Enhancing the Efficacy of Hepatocellular Carcinoma Chemotherapeutics with Natural Anticancer Agents.  Alisi A, Balsano C.  Nutr Rev., 2007 Dec; 65(12 Pt 1):550-3.
  69. Hepatitis C virus (HCV): an RNA virus with a pro-oncogenic potential.  Balsano C, Alisi A.  Dig Liver Dis, 2007 Sep; 39 Suppl 1:S46-51. doi: 10.1016/S1590-8658(07)80010-7
  70. Hepatits C virus core protein enhances B lymphocyte proliferation.  Alisi A, Giannini C, Spaziani A, Anticoli S, Caini P, Zignego AL, Balsano C.  Dig Liver Dis., 2007 Sep; 39 Suppl 1:S72-5.  doi: 10.1016/S1590-8658(07)80015-6.
  71. Role of p38MAPK and PKR in HCV core-dependent nuclear delocalization of cyclin B1.Spaziani A, Alisi A, Sanna D, Balsano C. J Biol Chem., 2006 Apr 21; 281(16):10983-9.
  72. HCV related transformation and new therapeutic strategies: an update. Balsano C, Alisi A.  Curr Cancer Ther Rev., 2006; 2(1), doi: 10.2174/157339406775471830.
  73. Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells. Alisi A, Mele R, Spaziani A, Tavolaro S, Palescandolo E, Balsano C. J Cell Physiol., 2005 Oct; 205(1):25-31.
  74. Physical and functional interaction between HCV core protein and the different p73 isoforms. Alisi A, Giambartolomei S, Cupelli F, Merlo P, Fontemaggi G, Spaziani A, Balsano C. Oncogene, 2003 May 1; 22(17):2573-80.
  75. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L. Porcellini A, Screpanti I, Balsano C, Alesse E, Gulino A, Levrero M. Nat Cell Biol.,2003 Jun; 5(6):552-8.
  76. p73 is regulated by phosphorylation at the G2/M transition.  Fulco M, Costanzo A, Merlo P, Mangiacasale R, Strano S, Blandino G, Balsano C, Lavia P, Levrero M. J Biol Chem., 2003 Dec 5; 278(49):49196-202.
  77. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest.  Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano C, Levrero M, Costanzo A. Oncogene, 2002 May 23; 21(23):3796-803.
  78. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C, Levrero M.  Mol Cell., 2002 Jan; 9(1):175-86.
  79. Prevalence and genomic variability of transfusion transmitted virus in Italian cryptogenic chronic liver disease and and healty blood donors.  Artini M, Almerighi C, Cariani E, Rossini A, Levrero M, Balsano C. Dig. Liver Dis, 2002 Aug;34(8):570-6.
  80. Sustained activation of Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein.  Giambartolomei S, Covone F, Levrero M, Balsano C.  Oncogene,2001 May 3; 20(20):2606-10.
  81. Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation.Giambartolomei S, Artini M, Almerighi C, Moavero SM, Levrero M, Balsano C.  Hepatology, 1999 Aug; 30(2):510-6.
  82. Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with a type 2 autoimmune hepatitis.  Pensati L, Costanzo A, Ianni A, Accapezzato D, Iorio R, Natoli G, Nisini R, Almerighi C, Balsano C, Vajro P, Vegnente A, Levrero M.  Gastroenterology, 1997 Oct; 113(4):1384-9.
  83. The hepatitis B virus X gene induces p53 mediated programmed cell death.  Chirillo P, Pagano S, Natoli G, Puri PL, Burgio VL, Balsano C, Levrero M.  Proc Natl Acad Sci USA, 1997 Jul 22; 94(15):8162-7.
  84. MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.  Puri PL, Balsano C, Burgio VL, Chirillo P, Natoli G, Ricci L, Mattei E, Graessmann A, Levrero M.  Oncogene, 1997 Mar 13; 14(10):1171-84.
  85. Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes.Puri PL, Medaglia S, Cimino L, Maselli C, Germani A, De Marzio E, Levrero M, Balsano C. J Cell Biochem., 1997 Jul 1; 66(1):27-36.
  86. p300 is required for MyoD dependent cell cycle arrest and muscle specific gene transcription.  Puri PL, Avantaggiati ML, Balsano C, Sang N, Graessmann A, Giordano A, Levrero M. EMBO J., 1997 Jan 15; 16(2):369-83.
  87. Tumor Necrosis Factor (TNF) Receptor 1 signaling downsteam of TNF receptor-associated factor 2.  Natoli G, Costanzo A, Moretti F, Fulco M, Balsano C, Levrero M.  J Biol Chem., 1997 Oct 17; 272(42):26079-82.
  88. Terapia dell'epatite da virus C. Trattamenti convenzionali e non.  Balsano C, Giambartolomei S, Artini M, Almerighi CG.  Gastroenterol., 1997; 2 n.3, 130-137.
  89. Activation of SAPK/JNK by TNF Receptor 1 through a noncytotoxic TRAF2-dependent pathway.Natoli G, Costanzo A, Ianni A, Templeton DJ, Woodgett JR, Balsano C, Levrero M. Science, 1997 Jan 10; 275(5297):200-3.
  90. Elevated serum levels of 90K/MAC-2BP predicts unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients.  Artini M, Natoli G, Tinari N, Costanzo A, Marinelli R, Balsano C, Porcari P, Angelucci D, D'Egidio M, Levrero M, Iacobelli S.  J Hepatol., 1996 Aug; 25(2):212-7.
  91. Hepatitis B virus pX activates NF-kB-dependent transcription through a Raf-independent pathway.Chirillo P, Falco M, Puri PL, Artini M, Balsano C, Levrero M, Natoli G. J Virology, 1996 Jan; 70(1):641-6.
  92. Infection of circulating and liver infiltrating T cells by hepatitis C virus of different subtypes. Artini M, Nisini R, Missale G, Costanzo A, Accapezzato D, Balsano C, Barnaba V, Levrero M.  Viral Immunol., 1995; 8(2):63-73.
  93. Resistance to Fas-mediated apoptosis in human hepatoma cells.  Natoli G, Ianni A, Costanzo A, De Petrillo G, Ilari I, Chirillo P, Balsano C, Levrero M.  Oncogene,1995 Sep 21; 11(6):1157-64.
  94. Reactive oxygen intermediates mediate angiotensin II-induced c-Jun/c-Fos heterodimer DNA binding activity and proliferative hypertrofic responses in myogenic cells.Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M. J Biol Chem., 1995 Sep 22; 270(38):22129-34.
  95. Modulation of intracellular signal transduction pathways by the hepatitis B virus transactivator pX.  Natoli G, Avantaggiati ML, Chirillo P, De Marzio E, Collepardo D, Falco M, Balsano C, Levrero M.  J Hepatol., 1995; 22(1 Suppl):14-20.
  96. Reactive oxygen intermediates (ROIs) are involved in the intracellular transduction of angiotensin II signal in C2C12 cells.  Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M. Ann NY Acad. Sci., 1995 Mar 27; 752:394-405.
  97. Ras- and Raf-dependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator pX. Natoli G, Avantaggiati ML, Chirillo P, Puri PL, Ianni A, Balsano C, Levrero M. Oncogene ,1994 Oct; 9(10):2837-43.
  98. Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with Hepatitis B virus. Barnaba V, Franco A, Paroli M, Benvenuto R, De Petrillo G, Burgio VL, Santillo I, Balsano C, Bonavita MS, Cappelli G, Colizzi V, Curtona G, Ferrarini M. J Immunol., 1994 Mar 15; 152(6):3074-87.
  99. Hepatitis B virus X gene product acts as a transactivator in vivo.  Balsano C, Billet O, Bennoun M, Cavard C, Zider A, Grimber G, Natoli G, Briand P, Levrero M. J Hepatol., 1994 Jul; 21(1):103-9.
  100. Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX.  Natoli G, Avantaggiati ML, Chirillo P, Costanzo A, Artini M, Balsano C, Levrero M. Mol Cell Biol., 1994 Feb; 14(2):989-98.
  101. Normalization of depressed natural killer activity after interferon-alfa therapy is associated with a low frequency of relapse in patients with chronic hepatitis C.Bonavita MS, Franco A, Paroli M, Santilio I, Benvenuto R, De Petrillo G, Levrero M, Perrone A, Balsano C, Barnaba V.  Int J Tissue React., 1993; 15(1):11-6.
  102. The Hepatitis B virus (HBV) pX transactivates the c-fos promoter through multiple cis-acting elements.  Avantaggiati ML, Natoli G, Balsano C, Chirillo P, Artini M, De Marzio E, Collepardo D, Levrero M. Oncogene, 1993 Jun; 8(6):1567-74.
  103. Characterization of the hepatitis B virus transactivators: a possible direct role of the virus in the development of hepatocellular carcinoma.Levrero M, Balsano C, Avantaggiati ML, Natoli G, Chirillo P, De Marzio E, Collepardo D, Costanzo A. J Surg Oncol.
  104. Detection of replicative intermediates of viral RNA in peripheral blood mononuclear cells from chronic hepatitis C virus carriers. Artini M, Natoli G, Avantaggiati ML, Balsano C, Chirillo P, Costanzo A, Bonavita MS, Levrero M. Arch Virol. Suppl., 1993; 8:23-29.
  105. The hepatitis B virus X gene product transactivates the HIV-LTR in vivo. Balsano C, Billet O, Bennoun M, Cavard C, Zider A, Grimber G, Natoli G, Briand P, Levrero M. Arch Virol. Suppl., 1993; 8:63-71.
  106. Characterization of the hepatitis B Virus preS/S region encoded transcriptional transactivator.  Natoli G, Avantaggiati ML, Balsano C, De Marzio E, Collepardo D, Elfassi E, Levrero M. Virology, 1992 Apr; 187(2):663-70.
  107. The hepatitis B virus X protein transactivation of c-fos and c-myc proto-oncogenes is mediated by multiple transcription factors.  Avantaggiati ML, Balsano C, Natoli G, De Marzio E, Will H, Elfassi E, Levrero M.  Arch Virol. Suppl., 1992; 4:57-61.
  108. Recombinant Immunoblot assay for hepatitis C virus antibody in chronic hepatitis.Taliani G, Badolato MC, Lecce R, De Bac C, De Marzio E, Balsano C, Artini M, Levrero M.  Arch. Virol. Suppl., 1992; 4:232-233.
  109. A second-generation hepatitis C virus confirmatory test for chronic hepatitis B virus Infection.  Taliani G, Lecce R, Badolato MC, De Bac C, De Marzio E, Balsano C, Artini M, Levrero M.  J Infect Dis., 1992 Jan; 165(1):180-1.
  110. The hepatitis B virus X protein transactivation of c-fos and c-myc proto-oncogenes is mediated by multiple transcription factors.Avantaggiati ML, Balsano C, Natoli G, De Marzio E, Will H, Elfassi E, Levrero M.  Arch Virol. Suppl., 1992; 4:57-61.
  111. Truncated pre-S/S proteins transactivate multiple target sequences. Natoli G, Balsano C, Avantaggiati ML, De Marzio E, Artini M, Collepardo D, Elfassi E, Levrero M. Arch. Virol. Suppl., 1992; 4:65-69.
  112. Significance of anti-HBx antibodies in hepatitis B virus infection. Levrero M, Stemler M, Pasquinelli C, Alberti A, Jean-Jean O, Franco A, Balsano C, Diop D, Brechot C, Melegari M, Villa E, Barnaba V, Perricaudet M, Will H. Hepatology, 1991 Jan; 13(1):143-9.
  113. Full-lengh and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cmyc protooncogene at the transcriptional level. Balsano C.,. Avantaggiati ML, Natoli G, De Marzio E, Will H, Perricaudet M, Levrero M. Biochem Biophys Res Commun., 1991 May 15; 176(3):985-92.
  114. Hepatitis B virus and hepatocellular carcinoma: a possible role for the viral transactivators. Levrero M, Balsano C, Avantaggiati ML, Natoli G, De Marzio E, Will H. Ital J Gastroenterol. 23, 576-583, 1991.
  115. Antibodies to hepatitis C virus in patients with hepatocellular carcinoma. Levrero M, Tagger A, Balsano C, De Marzio E, Avantaggiati ML, Natoli G, Diop D, Villa E, Diodati G, Alberti A.J Hepatol.,1991 Jan; 12(1):60-3.
  116. Defective and non defective adenovirus vectors for expressing foreign genes in vitro and in vivo. Levrero M, Barnaba V, Manteca S, Ballay A, Balsano C, Avantaggiati ML, Natoli G, Skellekens H, Tiollais P, Perricaudet M. Gene, 1991 May 30; 101(2):195-202.
  117. Hepatitis B virus X protein transactivates the long terminal repeats of human immunodeficiency virus types 1 and 2. Levrero M, Balsano C, Natoli G, Avantaggiati ML, Elfassi E. J Virol., 1990 Jun; 64(6):3082-3086.
  118. Hepatitis B virus (HBV) X gene expression in human cells and anti-HBx antibodies detection in chronic HBV infection. Levrero M, Jean-Jean O, Balsano C, Will H, Perricaudet M. Virology, 1990 Jan; 174(1):299-304.
  119. Liver derived T cell clones in autoimmune chronic active hepatitis: accessory cell function of hepatocytes expressing class II major hystocompatibility complex molecules. Franco A, Barnaba V, Ruberti G, Benvenuto R, Balsano C, Musca A. Clin Immunol Immunopathol., 1990 Mar; 54(3):382-94.
  120. Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection.Barnaba V, Franco A, Alberti A, Balsano C, Benvenuto R, Balsano F. J Immunol.,1989 Oct 15; 143(8):2650-5.
  121. Expression of class I and II major histocompatibility complex antigens on human hepatocytes. Franco A, Barnaba V, Natali PG, Balsano C, Musca A, Balsano F. Hepatology, 1988 May-Jun;8(3):449-54.

 

PUBBLICAZIONI senza I.F.

 

  • Repeated thrombolysis after early recurrent ischemic stroke within 48 hours: a case report

Romualdi R, Assetta M, Cerrone P, Casalena A, Di Giuseppe M, Sciamanna S, Balsano C

Italian Journal of Emergency Medicine, In Press

  • Pathogenesis of hepatocellular carcinoma: new ideas for a targeted therapy.

Arciello M, Balsano C.

Hot Topics in Viral Hepatitis. Women in hepatology 2nd ed. 2013; 27 Doi:10.4147/HTV-132727

  • Chronic viral hepatitis: its characteristics and management.

Brunetto MR, Balsano C, Burra P, Cariani E, Taliani G, Villa E.

Hot Topics in Viral Hepatitis. 7, 2011.

  • La steatoepatite non alcolica (NASH). Cenni diagnostici e terapeutici.

Balsano C, Mici E.

Il Caduceo, 2006.

  • Occult hepatitis B virus infection. 

Raimondo G, Balsano C, Craxi A, Farinati F, Levrero M, Mondelli M, Pollicino T, Squadrito G,

Tiribelli C.

Dig Liver Dis., 2000 Dec;32(9):822-6.

  • The molecular basis of myocardial hyperthrophy. 

Puri PL, Natoli G, Avantaggiati ML, Balsano C, De Marzio P, Levrero M.

Ann Ital Med Int. 1994; 9:160-165.

  • Ingegneria genetica e nuovi vaccini contro l'epatite B.

Levrero M, Natoli G, Avantaggiati ML.

Attualita' in Medicina Interna,1991; 5.

  • La tecnica di amplificazione enzimatica del DNA (PCR) nella diagnostica dell'infezione da CMV.

Mancini C, Curcio S, Padula C, Avantaggiati ML, Balsano C, Lorino G, Carattoli A, Levrero M. Microbiologia Medica, 1990; 3(5).

  • Ingegneria genetica e nuovi vaccini contro l'epatite B. 

Balsano C, Natoli G, Avantaggiati ML, Levrero M.

Attualita' in Medicina , 1990; 5.

  • La biologia molecolare del virus B dell'epatite.

Levrero M, Balsano C, Avantaggiati ML, Natoli G.

Attualita' in Medicina , 1990; 5.

  • Effetto in vitro dell'alfa interferone e della timomodulina sull'attivita' natural killer in pazienti con AIDS related complex. 

Paroli M, Balsano C, Valesini G, Biffoni M, Perrone A, Barnaba V.

Annali di Med. Interna, 1988; 3:39-44.

  • Autoimmunita' epatica. 

Barnaba V, Franco A, Ruberti G, Balsano C.

 

LIBRI

 

Oxidative stress, dysregulation of cell homeostasis and induction of cell trasformation

Editor: Balsano C, Research Signpost 37/661 (2).

Robot Therapy in Pediatric Emergency: Impact of Integrated Approach for Collaborative Patients

Rossi S, Di Giacomo D, Balsano C.

Olistic City: un paradigma possibile

Balsano C, Costantini S, De Gasperis G, Placidi G, Stilo G.

 

CAPITOLI in libri

 

  • What is oxidative stress?

Balsano C, Victor VM, Costanzo A.

  • Redox status alterations and metabolic disorders.

Alisi A, Balsano C.

Chapter 5, Research Signpost, 37/661 (2)

  • Role of oxidative stress in the pathogenesis of cancer

Balsano C, Alisi A.

  • Molecular basis of HCC.

Levrero M, Chirillo P, Balsano C, Natoli G.

  • Role of oxidative stress in the pathogenesis of cancer Reactive oxygen intermediates (ROIs) are involved in the intracellular transduction of angiotensin II signal in C2C12 cells.

Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M.

In: Cardiac Growth and Regeneration Ann. N. Y. Acad. Sci. Vol. 752, p. 394 (1995).

  • La Medicina D’Emergenza Oggi. Capitolo

Le basi molecolari dell'adattamento cardiaco ai sovraccarichi di lavoro.

Levrero M, De Marzio P, Avantaggiati ML, Natoli G, Balsano C.

  • Transactivation of fos and myc protoncogenes by both full length and truncated versions of the HBV-X protein.

Levrero M, Avantaggiati ML, Natoli G, Balsano C, De Marzio E, Elfassi E, Will H.

  • Comparative analysis of transactivation by HBV-X, adenovirus E1A and HIV tat proteins.C.

Balsano C, Levrero M, Chaigne-Crescenzo C, Pillot J, Elfassi E.

 

Sitemap

Fondazione F.B.

Altri Link

Contatti